|
7 Companies |
|
9 Products |
|
9 Products |
|
8 Mechanisms of Action |
|
0 Trials |
|
60 News |
|
| 12» |
- | davunetide intranasal (AL-108) / Endo
Phase classification: Davunetide (AL-108) in Predicted Tauopathies - Pilot Study (clinicaltrials.gov) - Apr 20, 2019
P1, N=12, Completed, Sponsor: University of California, San Francisco
Phase classification: P2 --> P1
- Kanuma (sebelipase alfa) / AstraZeneca
Trial completion, Trial primary completion date: VITAL: Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency (clinicaltrials.gov) - Jan 30, 2019
P2/3, N=9, Completed, Sponsor: Alexion Pharmaceuticals
Phase classification: P2 --> P1 Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Jan 2018
- | Trial completion: Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia (clinicaltrials.gov) - Aug 8, 2018
P2, N=52, Completed, Sponsor: Lawson Health Research Institute
Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Jan 2018 Recruiting --> Completed
- | Phase classification, Enrollment change: Living With Frontotemporal Dementia (clinicaltrials.gov) - Apr 6, 2018
P, N=16, Terminated, Sponsor: National Human Genome Research Institute (NHGRI)
Recruiting --> Completed Phase classification: P=N/A --> P | N=40 --> 16
- | Phase classification: QMFFTD: EEG Biofeedback to Improve Memory in Adults With Dementia (clinicaltrials.gov) - Apr 2, 2018
P=N/A, N=37, Completed, Sponsor: Quietmind Foundation
Phase classification: P=N/A --> P | N=40 --> 16 Phase classification: P2 --> P=N/A
- | davunetide intranasal (AL-108) / Endo
Trial completion: Davunetide (AL-108) in Predicted Tauopathies - Pilot Study (clinicaltrials.gov) - Mar 26, 2018
P2, N=12, Completed, Sponsor: University of California, San Francisco
Phase classification: P2 --> P=N/A Active, not recruiting --> Completed
- | amantadine / Generic mfg.
Enrollment change, Trial withdrawal: Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD) (clinicaltrials.gov) - Aug 14, 2017
P4, N=0, Withdrawn, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed N=52 --> 0 | Terminated --> Withdrawn
- | Trial completion: Double Blind Trial of DC Polarization in FTD (clinicaltrials.gov) - Jun 30, 2017
P2, N=20, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
N=52 --> 0 | Terminated --> Withdrawn Recruiting --> Completed
- | Trial completion: Treatment Study of Frontotemporal Dementia (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=20, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Test of A Model of Representational Knowledge Stored in the Human Prefrontal Cortex (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=949, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Active, not recruiting --> Completed Recruiting --> Completed
- | Trial completion, Trial primary completion date: ProsKuopio: Computational Tools for Early Diagnosis of Memory Disorders (clinicaltrials.gov) - May 3, 2017
P=N/A, N=126, Completed, Sponsor: University of Eastern Finland
Recruiting --> Completed Enrolling by invitation --> Completed | Trial primary completion date: Jun 2016 --> Apr 2017
- Trial completion, Enrollment change, Trial primary completion date: Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects (clinicaltrials.gov) - Dec 16, 2016
P1, N=16, Completed, Sponsor: Molecular NeuroImaging
Enrolling by invitation --> Completed | Trial primary completion date: Jun 2016 --> Apr 2017 Recruiting --> Completed | N=80 --> 16 | Trial primary completion date: Dec 2016 --> Aug 2016
- Zolinza (vorinostat) / Merck (MSD)
Trial completion, Enrollment change, Trial primary completion date: Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1 (clinicaltrials.gov) - Dec 15, 2016
P1/2, N=12, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting --> Completed | N=80 --> 16 | Trial primary completion date: Dec 2016 --> Aug 2016 Recruiting --> Completed | N=15 --> 12 | Trial primary completion date: Jun 2017 --> Dec 2016
- davunetide intranasal (AL-108) / Endo
Trial primary completion date: Davunetide (AL-108) in Predicted Tauopathies - Pilot Study (clinicaltrials.gov) - Dec 7, 2016
P2, N=12, Active, not recruiting, Sponsor: University of California, San Francisco
Recruiting --> Completed | N=15 --> 12 | Trial primary completion date: Jun 2017 --> Dec 2016 Trial primary completion date: Jul 2016 --> Jul 2017
- Trial completion, Trial primary completion date: Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells (clinicaltrials.gov) - Jun 23, 2016
P1/2, N=25, Completed, Sponsor: Children's Hospital Los Angeles
Trial primary completion date: Jul 2016 --> Jul 2017 Recruiting --> Completed | Trial primary completion date: Aug 2012 --> Aug 2015
- ||||||| LMTX (hydromethylthionine) / TauRx
Trial completion, Trial initiation date: Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) (clinicaltrials.gov) - Apr 11, 2016
P3, N=220, Completed, Sponsor: TauRx Therapeutics Ltd
Recruiting --> Completed | Trial primary completion date: Aug 2012 --> Aug 2015 Active, not recruiting --> Completed | Initiation date: Aug 2013 --> May 2013
- Trial primary completion date: Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects (clinicaltrials.gov) - Apr 9, 2016
P1, N=80, Recruiting, Sponsor: Molecular NeuroImaging
Active, not recruiting --> Completed | Initiation date: Aug 2013 --> May 2013 Trial primary completion date: Feb 2016 --> Dec 2016
- Trial termination: Living With Frontotemporal Dementia (clinicaltrials.gov) - Feb 29, 2016
P=N/A, N=40, Terminated, Sponsor: National Human Genome Research Institute (NHGRI)
Trial primary completion date: Feb 2016 --> Dec 2016 Recruiting --> Terminated
- davunetide intranasal (AL-108) / Endo
Trial primary completion date: Davunetide (AL-108) in Predicted Tauopathies - Pilot Study (clinicaltrials.gov) - Jan 28, 2016
P2, N=12, Active, not recruiting, Sponsor: University of California, San Francisco
Recruiting --> Terminated Trial primary completion date: Dec 2015 --> Jul 2016
- Enrollment change, Trial withdrawal, Trial primary completion date: A Composite MR Neuroimaging Marker for Alzheimer's Disease (clinicaltrials.gov) - Jan 15, 2016
P=N/A, N=0, Withdrawn, Sponsor: Medical College of Wisconsin
Trial primary completion date: Dec 2015 --> Jul 2016 N=380 --> 0 | Enrolling by invitation --> Withdrawn | Trial primary completion date: Mar 2014 --> Jan 2016
- Phase classification: PiB PET Scanning in Speech and Language Based Dementias (clinicaltrials.gov) - Dec 23, 2015
P1, N=168, Completed, Sponsor: Mayo Clinic
N=380 --> 0 | Enrolling by invitation --> Withdrawn | Trial primary completion date: Mar 2014 --> Jan 2016 Phase classification: P=N/A --> P1
- Phase classification: Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD (clinicaltrials.gov) - Dec 21, 2015
P1, N=27, Completed, Sponsor: Mayo Clinic
Phase classification: P=N/A --> P1 Phase classification: P=N/A --> P1
- Enrollment open: ProsKuopio: Computational Tools for Early Diagnosis of Memory Disorders (clinicaltrials.gov) - Dec 15, 2015
P=N/A, N=120, Enrolling by invitation, Sponsor: University of Eastern Finland
Phase classification: P=N/A --> P1 Active, not recruiting --> Enrolling by invitation
- Trial completion: Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD (clinicaltrials.gov) - Sep 8, 2015
P=N/A, N=27, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Enrolling by invitation Recruiting --> Completed
- Trial completion, Enrollment change: Assessment of Social-emotional Functioning in Neurological Diseases (clinicaltrials.gov) - Sep 8, 2015
P=N/A, N=177, Completed, Sponsor: Centre Hospitalier Universitaire, Amiens
Recruiting --> Completed Recruiting --> Completed | N=320 --> 177
- davunetide intranasal (AL-108) / Endo
Trial primary completion date: Davunetide (AL-108) in Predicted Tauopathies - Pilot Study (clinicaltrials.gov) - Jun 11, 2015
P2, N=12, Active, not recruiting, Sponsor: University of California, San Francisco
Recruiting --> Completed | N=320 --> 177 Trial primary completion date: Dec 2014 --> Dec 2015
- ||||| LMTX (hydromethylthionine) / TauRx
Enrollment closed, Enrollment change: Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) (clinicaltrials.gov) - Mar 20, 2015
P3, N=220, Active, not recruiting, Sponsor: TauRx Therapeutics Ltd
Trial primary completion date: Dec 2014 --> Dec 2015 Recruiting --> Active, not recruiting | N=180 --> 220
- ||| Trial completion: PiB PET Scanning in Speech and Language Based Dementias (clinicaltrials.gov) - Mar 18, 2015
P=N/A, N=168, Completed, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting | N=180 --> 220 Recruiting --> Completed
- Trial completion, Enrollment change: Language Treatment for Progressive Aphasia (clinicaltrials.gov) - Jan 28, 2015
P=N/A, N=7, Completed, Sponsor: Baycrest
Recruiting --> Completed Active, not recruiting --> Completed | N=14 --> 7
- Trial primary completion date: Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD (clinicaltrials.gov) - Nov 28, 2014
P=N/A, N=30, Recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed | N=14 --> 7 Trial primary completion date: Oct 2014 --> Apr 2015
- | Enrollment change: Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls. (clinicaltrials.gov) - Sep 19, 2014
P2, N=34, Completed, Sponsor: Avid Radiopharmaceuticals
Trial primary completion date: Oct 2014 --> Apr 2015 N=28 --> 34
- ||| Trial completion, Trial primary completion date: Longitudinal Study of Cognition With Niemann-Pick Disease, Type C (clinicaltrials.gov) - Sep 12, 2014
P=N/A, N=70, Completed, Sponsor: Mayo Clinic
N=28 --> 34 Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Sep 2014
- |||| LMTX (hydromethylthionine) / TauRx
Trial primary completion date: Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) (clinicaltrials.gov) - Aug 6, 2014
P3, N=180, Recruiting, Sponsor: TauRx Therapeutics Ltd
Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Sep 2014 Trial primary completion date: Jul 2015 --> Dec 2015
- davunetide intranasal (AL-108) / Endo
Trial primary completion date: Davunetide (AL-108) in Predicted Tauopathies - Pilot Study (clinicaltrials.gov) - Jul 10, 2014
P2, N=12, Active, not recruiting, Sponsor: University of California, San Francisco
Trial primary completion date: Jul 2015 --> Dec 2015 Trial primary completion date: Dec 2013 --> Dec 2014
- Trial termination: UCBT-002: ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases (clinicaltrials.gov) - Jul 8, 2014
P3, N=40, Terminated, Sponsor: Aldagen
Trial primary completion date: Dec 2013 --> Dec 2014 Suspended --> Terminated; Terminated - Sponsor Decision
- Kanuma (sebelipase alfa) / AstraZeneca
Enrollment closed: VITAL: Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency (clinicaltrials.gov) - May 20, 2014
P2/3, N=10, Active, not recruiting, Sponsor: Synageva BioPharma Corp.
Suspended --> Terminated; Terminated - Sponsor Decision Recruiting --> Active, not recruiting
- Zolinza (vorinostat) / Merck (MSD)
New P1/2 trial: Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1 (clinicaltrials.gov) - Apr 24, 2014
P1/2, N=15, Recruiting, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Enrollment change: Living With Frontotemporal Dementia (clinicaltrials.gov) - Apr 18, 2014
P=N/A, N=40, Recruiting, Sponsor: National Human Genome Research Institute (NHGRI)
Recruiting --> Active, not recruiting N=60 --> 40
- New P1 trial: Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects (clinicaltrials.gov) - Apr 2, 2014
P1, N=80, Recruiting, Sponsor: Molecular NeuroImaging
- ||| Biomarker, Trial completion: Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION (clinicaltrials.gov) - Mar 5, 2014
P=N/A, N=204, Completed, Sponsor: Neuronetrix, Inc.
N=60 --> 40 Recruiting --> Completed
- | Trial completion: Direct Current Brain Polarization in Frontotemporal Dementia (clinicaltrials.gov) - Feb 22, 2014
P1, N=6, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting --> Completed Recruiting --> Completed
- Xenpozyme (olipudase alfa) / Sanofi
Trial completion: Tolerability and Safety Study of Recombinant Human Acid Sphingomyelinase in Acid Sphingomyelinase Deficiency Patients (clinicaltrials.gov) - Jan 15, 2014
P1, N=5, Completed, Sponsor: Genzyme, a Sanofi Company
Recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: FTDOXY10EF: Safety Study of Intranasal Oxytocin in Frontotemporal Dementia (clinicaltrials.gov) - Oct 31, 2013
P1, N=23, Completed, Sponsor: Lawson Health Research Institute
Active, not recruiting --> Completed Recruiting --> Completed
- ||||| LMTX (hydromethylthionine) / TauRx
Trial initiation date: Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) (clinicaltrials.gov) - Oct 8, 2013
P3, N=180, Recruiting, Sponsor: TauRx Therapeutics Ltd
Recruiting --> Completed Initiation date: Feb 2013 --> Aug 2013
- Enrollment open: Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia (clinicaltrials.gov) - Oct 3, 2013
P2, N=72, Recruiting, Sponsor: Lawson Health Research Institute
Initiation date: Feb 2013 --> Aug 2013 Not yet recruiting --> Recruiting
- | New P2 trial: Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia (clinicaltrials.gov) - Sep 5, 2013
P2, N=72, Recruiting, Sponsor: Lawson Health Research Institute
- | New P2 trial: Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls. (clinicaltrials.gov) - Jun 27, 2013
P2, N=28, Completed, Sponsor: Avid Radiopharmaceuticals
- Xenpozyme (olipudase alfa) / Sanofi
Trial initiation date: Tolerability and Safety Study of Recombinant Human Acid Sphingomyelinase in Acid Sphingomyelinase Deficiency Patients (clinicaltrials.gov) - Mar 26, 2013
P1, N=5, Completed, Sponsor: Genzyme, a Sanofi Company
Not yet recruiting --> Recruiting Initiation date: Dec 2012 --> Mar 2013
- |||||| LMTX (hydromethylthionine) / TauRx
Enrollment open: Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) (clinicaltrials.gov) - Mar 26, 2013
P3, N=180, Recruiting, Sponsor: TauRx Therapeutics Ltd
Initiation date: Dec 2012 --> Mar 2013 Not yet recruiting --> Recruiting
- Enrollment open: Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD (clinicaltrials.gov) - Mar 19, 2013
P=N/A, N=30, Recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting